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Hormonal-receptor positive (HRP) breast cancer patients with positive metastatic axillary
lymph nodes are characterized by poor prognosis and increased mortality rate. The mechanisms
by which cancer cells invade lymph nodes have not yet been fully explored. Several studies have
shown that expression of IL-6 and the proteolytic enzyme cathepsin B (CTSB) was associated
with breast cancer poor prognosis. In the present study, the effect of different concentrations
of recombinant human IL-6 on the invasiveness capacity of HRP breast cancer cell line
MCF-7 was tested using an in vitro invasion chamber assay. The impact of IL-6 on expression
and activity of CTSB was also investigated. IL-6 treatment promoted the invasiveness potential
of MCF-7 cells in a dose-dependent manner. Furthermore, MCF-7 cells displayed elevated
CTSB expression and activity associated with loss of E-cadherin and upregulation of vimentin
protein levels upon IL-6 stimulation. To validate these results in vivo, the level of expression of
IL-6 and CTSB in the carcinoma tissues of HRP-breast cancer patients with positive and neg-
ative axillary metastatic lymph nodes (pLNs and nLNs) was assessed. Western blot and
immunohistochemical staining data showed that expression of IL-6 and CTSB was higher in
carcinoma tissues in HRP-breast cancer with pLNs than those with nLNs patients. ELISA
results showed carcinoma tissues of HRP-breast cancer with pLNs exhibited significantly ele-
vated IL-6 protein levels by approximately 2.8-fold compared with those with nLNs patients
(P< 0.05). Interestingly, a significantly positive correlation between IL-6 and CTSB expression
was detected in clinical samples of HRP-breast cancer patients with pLNs (r= 0.78, P< 0.01).
Collectively, this study suggests that IL-6-induced CTSB may play a role in lymph node metas-
tasis, and that may possess future therapeutic implications for HRP-breast cancer patients with
pLNs. Further studies are necessary to fully identify IL-6/CTSB axis in different molecular sub-
types of breast cancer.
 2016 Production and hosting by Elsevier B.V. on behalf of Cairo University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Breast cancer is the second leading cause of cancer death
among women worldwide [1]. A study on 359 patients showed
that approximately 44% of breast cancer patients in Egypt
belong to luminal A molecular subtype which is considered
to be the most prevalent subtype in both early- and
advanced-stage disease [2]. The carcinoma cells of this subtype
are characterized by positive estrogen receptor (ER+) and/or
progesterone receptor (PR+) and negative human epidermal
growth factor receptor (HER2) [2]. Lymph node metastasis
status is considered as one of the important predictors for
breast cancer progression and the increase in the number of
positive metastatic lymph nodes contributes to poor survival
outcomes. In addition, each positive metastatic lymph node
was found to increase the risk of breast cancer death by
approximately 6% [3]. A previous study [4] showed that about
70% of Egyptian breast cancer patients with luminal A molec-
ular subtype also show positive metastatic lymph nodes.
Although different therapeutic approaches exist, studies using
large cohorts showed that patients diagnosed with 10 or more
positive lymph nodes have a 70% chance of tumor relapse
[4–6]. Therefore, understanding the mechanism(s) underlying
how carcinoma cells invade axillary lymph nodes is highly
warranted.
The multifunctional proteolytic enzyme cathepsin B
(CTSB) plays an important role in cancer progression [7–9].
Because of its increased and redistributed expression pattern
in human cancers, pro- or active CTSB is considered a marker
for invasion and metastasis of various carcinoma cells [10].The increases in CTSB expression level and activity as well
as alterations in tracking, localization and secretion of the
enzyme have been observed in many cancers such as oral car-
cinoma [11], colorectal [12], lung [13], ovarian [14] and
endometrial [15] . Localization of CTSB within the cell surface
has been shown in different types of invasive cancer cells, e.g.
breast [16], ovarian [17] and prostate [18] cancer. Invasive car-
cinoma cells showed altered lysosomal localization of CTSB
from perinuclear to peripheral regions and secretion of CTSB
into the extracellular space [19]. CTSB was found to bind with
the annexin II heterotetramer in the cell surface caveolae (lipid
raft) of invasive carcinoma cells [20,21]. This binding seems to
facilitate conversion of pro-CTSB to its active form [21,22]. In
the caveolae active CTSB may convert the pro-form of
urokinase-type plasminogen activator (pro-uPA) into active
uPA [21]. Thus, CTSB plays an important role in activation
of pericellular proteases and digestion of extracellular matrix
(ECM) proteins which facilitate breast cancer motility and
invasion [20]. A previous study conducted by the authors
and colleagues showed proteolytic activity of CTSB and its
co-expression with caveolin-1 induced motility and invasion
of the inflammatory breast cancer (IBC) cells [8]. Furthermore,
inhibition of CTSB using the enzyme specific inhibitor CA074
reduced the degradation of ECM proteins, invasion and motil-
ity of IBC cell lines [8].
Interleukin-6 (IL-6) has been shown to stimulate aromatase
expression in adipose tissue thus stimulating estrogen synthesis
and potentially contributing to breast cancer progression [23].
Moreover, IL-6 was found to induce expression of CTSB
through different signaling pathways. For instance, the
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stimulated expression of CTSB and cathepsin L (CTSL) in
human gingival fibroblasts through the c-Jun N-terminal
kinase-activator protein-1 (JNK-AP-1) caveolae involved
pathway [24]. In addition, IL-6 and cyclic adenosine
monophosphate (cAMP) were found to stimulate the secretion
of CSTB from human osteoblasts [25]. However, the impact of
IL-6 stimulation on CTSB expression and activity in breast
cancer has not yet been fully elucidated.
The aim of the present study was to investigate the effect of
different concentrations of IL-6 on the invasive potential of the
human HRP-breast cancer cell line MCF-7 and to evaluate
expression and activity of CTSB as a downstream mechanistic
cue for IL-6 stimulation. Furthermore, the association between
IL-6 expression and CTSB levels in carcinoma tissues of HRP-
breast cancer patients with positive lymph node (pLNs) vs neg-
ative lymph nodes (nLNs) was assessed. This study demon-
strated the role played by IL-6 in regulating expression and
activity of CTSB-mediated invasion and lymph node metasta-
sis in HRP-breast cancer.
Material and methods
Materials
Culture media and tissue culture supplies were from Lonza
(Lonza, Verviers, Belgium). CTSB antibody was a gift from
Dr. Bonnie Sloane (Department of Pharmacology, School of
Medicine, Wayne State University, Detroit, MI, USA).
Recombinant human IL-6 was purchased from R&D Systems
(R&D Systems, Wiesbaden, Germany). All other chemicals
were from Sigma (Sigma-Aldrich, Deisenhofen, Germany)
unless otherwise stated.
Patients’ samples
Patients diagnosed with HRP-breast cancer were recruited
from the breast cancer clinic of Ain-Shams University hospi-
tals during the period from December 2011 till December
2013. The approval of ethics committee of Ain-Shams University
hospital was obtained and all patients signed a consent form
before enrolling in this study. Depending on clinical and patho-
logical diagnosis the patients were divided into 2 groups: the
first group (n= 14) comprised of nLNs that showed no meta-
static axillary lymph nodes and the second group (n= 14) was
of pLNs patients with more than 4 metastatic axillary lymph
nodes. Each tissue specimen was divided into two halves: the
first half was fixed in 10% neutral formalin buffered for
histopathological diagnosis and immunohistochemistry and
the other half was snap frozen in liquid nitrogen for further
studies.
Cell culture
The human breast cancer cell line MCF-7 was a gift from Dr.
Bonnie F. Sloane (Department of Pharmacology, School of
Medicine, Wayne State University, Detroit, MI, USA).
MCF-7 cells were maintained in RPMI-1640 media supple-
mented with 10% fetal bovine serum (FBS), 1% glutamine,1% penicillin/streptomycin in a humidified atmosphere of
5% CO2 at 37 C.
Invasion assay
Cellular invasion of breast cancer cells was assessed using BD
BioCoatTM MatrigelTM Invasion Chamber (Becton Dickinson
Labware, Franklin Lakes, NJ, USA). MCF-7 cells at a density
of 2.5  104 per well were seeded in the upper chamber with
RPMI-1640 serum free media. The lower chambers were filled
either with 500 lL of RPMI-1640 media supplemented with
3% FBS (control), or with different concentrations of IL-6
(10 ng/mL, 25 ng/mL and 50 ng/mL) in RPMI supplemented
with 3% FBS. After 72 h of incubation the experiments were
stopped and cells were fixed and stained as described before
[26]. Non-invasive cells that remained in Matrigel or were
attached to the upper side of the filter were removed with cot-
ton swabs. Cells on the lower side of the filter, which invade in
response to different concentrations of IL-6, were stained using
the Diff-Quik staining kit (Dade-Behring, Inc., Englewood
Cliffs, NJ, USA) and counted using light microscopy. Invasive
cells were quantified by counting three random microscopic
fields and expressed as number of invaded cells.
Preparation of MCF-7 cell lysates
MCF-7 cells were grown at a density of 250,000 cell/mL in
30 mm Petri dishes containing RPMI-1640 supplemented with
10% FBS for 48 h at 37 C in a humidified CO2 incubator.
After 48 h cells were washed with PBS and grown in RPMI-
1640 media supplemented with 3% FBS and different concen-
trations of recombinant human IL-6 (10 ng/mL, 25 ng/mL and
50 ng/mL). Experiments were run in triplicate for each concen-
tration of recombinant human IL-6. Control MCF-7 cells were
grown in RPMI-1640 supplemented with 3% FBS. After 48 h
of incubation cells were washed three times with PBS and incu-
bated overnight in serum free media. Overnight media were
collected and stored at 80 C for future experiments. Cells
were washed twice with PBS at 4 C and collected by scraping
with rubber policeman in lysis buffer (250 mM sucrose, 25 mM
2-(4-morpholino) ethanesulfonic acid (MES), pH 7.5, 1 mM
EDTA, 0.1% Triton X-100). Cell lysates were sonicated on
ice in a 50 W Ultrasonicator five times for five seconds each
as described before [27].
CTSB activity assay
Activity of CTSB in MCF-7 cell lysates was assessed as
described previously [27,28]. One part of cell lysates was
diluted in 7 parts of activator buffer (5 mM EDTA, 10 mM
dithiothreitol (DTT), pH 5.2) and the mixture was incubated
for 15 min at 37 C. 100 lL of this mixture was added to
200 lL assay buffer containing a fluorometric CTSB substrate
(ZArg-Arg-NHMec). Fluorescence was measured at 1-min
interval for 30 min with excitation at 360 nm and emission at
465 nm using a Tecan-Spectrafluor Plus plate reader. Data
were expressed as picomoles of NHMec formed per minute
per lg DNA. Concentrations of DNA were assessed using
SYBR green method against a standard curve of salmon-
sperm DNA.
Fig. 1 IL-6 induces invasion of MCF-7 cells. (A) Equal numbers
of MCF-7 cells were seeded and incubated with control media
(RPMI-1640/3% FBS), 10, 25, and 50 ng/mL IL-6 for 72 h on BD
invasion chambers. MCF-7 cells that had invaded through the
filters were stained using Diff-Quik Stain Set (blue), and the
number of cells was counted in three random microscopic fields.
(B) Representative images of stained invasion filters. Results are
representative of three independent experiments. Data are
expressed as mean ± SD. * represents P< 0.05 as determined
by Student’s t-test, scale bar = 150 lm.
Table 1 Overview on the number of invaded MCF-7 cells
upon stimulation with different concentration of IL-6.
Cells Average number of
invaded cells/field ± SD
P-value
Control 33.5 ± 0.479
10 ng/mL IL-6 47.5 ± 0.46 0.0006
25 ng/mL IL-6 69.75 ± 0.77 0.0097
50 ng/mL IL-6 78.5 ± 0.67 0.002
Data are expressed as mean ± SD, n= 3.
P value was calculated by Student’s t-test.
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(SDS-PAGE) and immunoblot analysis of CTSB
For SDS-PAGE, protein concentration of total MCF-7 cells
and homogenized human breast cancer tissue lysates was first
determined using the Bradford assay. Both lysates were
reduced and separated by SDS-PAGE (12% acrylamide) at
protein concentration of 20 lg/well. Gels were electrotrans-
ferred onto nitrocellulose membranes and detection was per-
formed with primary antibody against CTSB (1:4000) and
secondary antibody conjugated with horseradish peroxidase
(1:10,000) in 5% (w/v) non-fat dry milk dissolved in Tris-
buffered saline washing buffer [TBS, (20 mM Tris, pH 7.5,
0.5 M NaCl)] containing 0.5% Tween-20. After washing,
specifically bound antibodies were detected by tetramethyl
benzidine (TMB) chromogen/substrate and the reaction was
stopped by immersing the membrane in water for 20–30 s.
All the above-mentioned steps were analogously repeated for
the detection of IL-6 levels in breast carcinoma tissue using
anti-human IL-6 antibody (R&D Systems, Wiesbaden, Ger-
many). Bands intensity was quantified with ImageJ software
(National Institutes of Health, Bethesda, MA, USA) using b-
actin as loading control.
Immunocytochemical staining
For immunocytochemical staining of CTSB, MCF-7 cells were
seeded at a density of 20  103 on glass cover-slips in RPMI-
1640 supplemented with 3% FBS and different concentrations
of recombinant IL-6 (10 ng/mL, 25 ng/mL and 50 ng/mL) for
48 h. To immunolocalize intracellular CTSB, MCF-7 cells
seeded in different concentrations of IL-6 were washed four
times with PBS and fixed with methanol (20 C) for 5–
10 min. Cells were then permeabilized with 2% saponin in
PBS and blocked by incubating with 0.5% bovine serum albu-
min in PBS. CTSB intracellular staining was carried out as pre-
viously described [29]. The primary antibodies used were
rabbit anti-human CTSB (5 lg/mL), mouse anti-human E-
cadherin (BD Bioscience CA, USA) and rabbit anti-human
vimentin (Santa Cruz Biotech, CA, USA). The secondary anti-
bodies used were fluorescein-conjugated affinity-purified don-
key anti-rabbit IgG and Texas red-conjugated affinity-
purified donkey anti-mouse IgG (20 lg/mL) in 5% normal
donkey serum. Cell nuclei were visualized by 40,60-diamidino-
2-phenylindole (DAPI) staining (Sigma, Deisenhofen, Ger-
many). Control samples were run in parallel but the primary
antibody was omitted. Coverslips were mounted with anti-
fade reagent and were analyzed with a Zeiss Axiovert micro-
scope (Zeiss, Oberkochen, Germany) at 40X magnification.
Immunohistochemical staining of CTSB of human HRP-breast
cancer tissues
Immunohistochemical staining for CTSB in carcinoma tissues
of breast cancer patients was performed as described previ-
ously [9]. Formalin-fixed and paraffin-embedded tumor tissues
were briefly deparaffinized in xylene and rehydrated through
graded ethanol. After antigen retrieval processing in a steamer,
tissue sections were incubated for one hour at room tempera-
ture with the CTSB primary antibody (1:500) diluted in Dako
antibody diluent. Detection was carried out by incubatingtissue sections with 100 lL of the secondary HRP-labeled rab-
bit antibody for 45 min and staining was developed with 3-30-
diaminobenzidine (DAB) for 15 min. Negative controls, in
which the primary antibody was omitted, were run in parallel.
The stained slides were analyzed semi-quantitatively using
imageJ software (National Institutes of Health, Bethesda,
MD, USA).
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ELISA was performed according to the manufacturer’s
instruction with Human IL-6 Quantikine ELISA (R&D Sys-tems). Equal protein concentration of total tissue homogenates
of HRP-breast cancer with pLNs and nLNs patients was
utilized.
Statistical analysis
Results were analyzed using SPSS (SPSS, Chicago, IL, USA),
version 15.0. Differences among variables were evaluated using
v2 analysis, Pearson’s rank correlation test, Fischer’s exact test
and Student’s t-test. Data were expressed as mean ± SEM.
Differences were considered statistically significant at
P< 0.05.
Results
IL-6 enhances invasive phenotype of MCF-7 cells in a dose-
dependent manner
BD-invasion chambers were used to test whether IL-6 as an
exogenous stimulant may alter invasiveness of MCF-7 cells.
Indeed, IL-6 showed chemotactic properties and induced inva-
sion of MCF-7 cells through Matrigel-coated filters in a dose-
dependent manner. The present results revealed that direc-
tional invasiveness was significantly enhanced by 42%, 107%
and 134% in presence of 10, 25, and 50 ng/mL IL-6, respec-
tively, as compared to control cells (P< 0.05) (Fig. 1A & B
and Table 1).
IL-6 augments expression and activity of CTSB in MCF-7 cells
Influence of different concentrations of IL-6 (10, 25, and
50 ng/mL) on expression of CSTB protein level in MCF-7 cells
was tested. IL-6 induced the expression and activity of CTSB
in a dose-dependent manner. IL-6 at concentrations of 25
and 50 ng/mL resulted in an increase in the cellular activity3
Fig. 2 Activity profile and expression of CSTB are increased in
MCF-7 cells stimulated by different concentrations of IL-6. (A)
Concentrations of 25 and 50 ng/mL of IL-6 induced a significant
increase in CTSB activity (P= 0.015129 and P= 0.003182,
respectively) as compared to control cells grown in RPMI-1640/
3% FBS culture media. Data are expressed as mean ± SD. (B)
Immunoblotting of CTSB expression in MCF-7 cells induced with
different concentrations of IL-6. (C) Immunocytochemical stain-
ing of CTSB in MCF-7 cells stimulated with different concentra-
tions of IL-6. Intracellular CTSB was detected by
immunofluorescence using a CTSB specific antibody. Control
MCF-7 cells seeded in RPMI-1640/3% FBS media show weak
expression of CTSB (green fluorescence), which increases gradu-
ally with increasing IL-6 concentration. DIC shows a fusiform
phenotype of MCF-7 cells with 50 ng/mL IL-6 treatment. Blue
color indicates DAPI nuclear staining. (D) Immunofluorescence
staining of E-cadherin and vimentin in control and 50 ng/mL IL-
6-treated MCF-7 cells for 24 h. IL-6 treatment of MCF-7 cells
decreases E-cadherin expression (green fluorescence, cells labeled
with asterisk) and enhances expression of vimentin (red fluores-
cence, cells labeled with arrow), suggestive acquisition of migra-
tory phenotype.
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(Fig. 2A). Moreover, the mature active forms of CTSB (single
chain (31 kDa) and double chain (25/26 kDa)) were highly
detected in cell lysates of MCF-7 cells stimulated by 25 and
50 ng/mL IL-6 (Fig. 2B).
The effect of IL-6 on the EMT process and CTSB expres-
sion in MCF-7 cells was further evaluated. Immunostaining
results indicate that upon increasing the concentration of IL-
6, MCF-7 cells lost cell-cell contact and acquired fibroblastic
shape with increased CTSB expression (Fig. 2C). This substan-
tiates that IL-6 enhanced EMT as reflected by loss of
E-cadherin expression and increased vimentin expression in
MCF-7 cells upon 50 ng/mL IL-6 treatment as determined
by immunofluorescence microscopy (Fig. 2D). Occasionally,
nuclear localization of CTSB, which was obviously increased
at the concentration of 50 ng/mL IL-6 (Fig. 2C) was observed,
and although speculative this suggests a transcriptional activ-
ity function.
IL-6 and CTSB expressions are upregulated in carcinoma tissues
of HPR-breast cancer with pLNs patients
The clinical and pathological characteristics of ER+, PR+,
HER patients included in this study are represented in
Table 2. The carcinoma tissues of pLNs patients are character-
ized by a statistically significant increase in lymphovascular
invasion (P= 0.034) as compared to nLNs patients. No other
clinical-pathological data showed statistical significance
between both groups of patients.
As the HRP-breast cancer cell line MCF-7 exhibited an
invasive phenotype via IL-6-mediated upregulation of CTSB
expression, this finding was tested in vivo using carcinoma tis-
sues of breast cancer patients. Therefore, the expression level
of IL-6 and CTSB in human breast carcinoma tissues obtainedTable 2 Clinical and pathological characterization of nLN and pL
Characteristics nLNs (ER+, PR+, HER2)
(N= 14)
Age
Range 27–78
Mean ± SD 56.64 ± 14.383
NA 0
Tumor size
64 1(7.14%)
>4 13 (92.86%)
NA 0
Tumor grade
G1 1 (7.14%)
G2 1 (7.14%)
G3 12 (85.71%)
G4 0
NA 0
Lymphovascular invasion
Negative 14 (100%)
Positive 0
NA 0
Data are expressed as mean ± SD.
NA: Data not available.
* Significant P value was calculated by aStudent’s t-test or bFisher’s exduring modified radical mastectomy of HRP-breast cancer
with nLNs and pLNs patients was assessed. Western blot data
revealed a significant upregulation of IL-6 and CTSB expres-
sion in carcinoma tissues of pLNs as compared to nLNs
patients (P< 0.05 and P< 0.01, respectively) (Fig. 3A & B
and Suppl. Table 1). The mature active forms of CTSB (single
chain (31 kDa) and double chain (25/26 kDa)) were more
prominent in pLNs as compared to nLNs breast cancer
patients. To test whether a correlation between CTSB and
IL-6 expression exists, Pearson’s rank correlation in nLNs
(n= 10) and pLNs (n= 10) was used. A significant positive
correlation (r= 0.78, P< 0.01) between the expression of
IL-6 and CTSB in carcinoma tissues of pLNs but not in nLNs
breast cancer patients was found (Fig. 3C). ELISA results
uncovered a 2.8-fold increase in IL-6 protein levels in carci-
noma tissues of HRP with pLNs compared with those nLNs
patients (P< 0.05) (Fig. 3D). IHC staining for CTSB in nLNs
and pLNs carcinoma tissues confirmed Western blot results:
carcinoma tissues of pLNs patients expressed higher CTSB
than those of nLNs (Fig. 3E). The present results support
the hypothesis of the potential role that may be played by
IL-6 in regulating CTSB expression and activity in breast can-
cer tissues.
Discussion
Cytokines are key regulatory molecules secreted by stromal
cells as well as tumor cells in the breast tumor microenviron-
ment [30,31]. IL-6 is one of the major cytokines secreted within
the tumor microenvironment by breast cancer cells-associated
monocytes [27] and adipocytes [32]. IL-6 was found to have
multiple tumor promoting functions [33] via stimulating prolif-
eration and inhibiting apoptosis [31,34]. For example, IL-6
secreted from adipose stromal cells was found to induce inva-N patients.
pLNs (ER+, PR+, HER2)
(N= 14)
P-value
31–70 0.352a
51.71 ± 13.076
0
3 (21.43%) 0.472b
11 (78.57%)
0
0 0.513b
2 (14.29%)
12 (85.71%)
0
0
11 (78.57%) 0.034*b
3 (21.43%)
0
act test.
Fig. 3 Up-regulation of IL-6 and CSTB expression in carcinoma tissues of HRP-breast cancer with pLNs as compared to those with
nLNs patients. (A) Representative Western blot of IL-6 and CTSB expression in 5 patients. (B) Densitometric analysis of Western blot
shows a significant upregulation of expression levels of IL-6 and CTSB in carcinoma tissues of HRP with pLNs (n= 10) as compared to
those with nLNs (n= 10). (C) A positive correlation between IL-6 and CTSB expression in HRP-breast cancer patients with pLN
(n= 10) as analyzed by a Pearson’s correlation. (D) Carcinoma tissues of HRP with pLNs (n= 10) breast cancer patients exhibit higher
IL-6 protein levels than those of nLNs (n= 14), as quantified by ELISA. * represents P< 0.05 and ** represents P< 0.01 as determined
by Student’s t-test. (E) Representative immunohistochemical staining of higher CTSB expression in carcinoma tissue of HRP-breast
cancer with pLNs (n= 14) as compared to those with nLNs (n= 14). Scale bar = 100 lm, arrow points to CTSB staining.
IL-6 and cathepsin B in hormonal-receptor positive breast cancer 667sion of MCF-7 breast cancer cells [32]. Moreover, it is also
documented that both IL-6 and its receptors (IL-6R and
sIL-6R) are overexpressed in breast carcinoma tissues [35].
Therapeutic targeting via monoclonal antibodies either against
IL-6 or IL-6R has been reported to be used in phase I/II clin-
ical trials in several tumor entities as reported before [31].
The aim of this study was to explore the effect of IL-6 on
non-invasive phenotype of HPR-breast cancer cell line MCF-
7. Data of this study revealed that IL-6 induced invasion of
breast carcinoma cells in vitro in a dose-dependent manner.
Furthermore, loss of cell-cell contact with acquisition of
fibroblastic phenotype via loss of E-cadherin expression and
upregulation by vimentin was prominent in MCF-7 cells upon
stimulation with IL-6. These findings are in agreement with
two reports: In a study using the orthotopic xenograft MCF-
7IL-6 breast cancer model, IL-6 was found to induce EMT phe-
notype via over-expression of vimentin and repression of E-cadherin. In addition, mice bearing MCF-7IL-6 xenograft
tumors possessed higher invasive and metastatic properties
as compared to control MCF-7 xenograft mice models [36].
A recent study [37] showed that over-expression of IL-6
induced invasion and lymph node metastasis in gallblad-
der cancer via stimulation of EMT molecular mechanism.
CTSB, a lysosomal cysteine protease, is considered as a
‘‘multifunctional enzyme in cancer” and essentially contributes
to the proteolytic cascades associated with tumor progression
including growth, invasion and metastasis [7]. Mechanistically,
CTSB initiates proteolytic cascades on the surface of cancer
cells which ultimately result in the activation of downstream
proteases such as uPA, pro-matrix metalloproteinases
(MMP)-2 and -9 that degrade ECM components and adhesion
molecules (E-cadherin) [7,38–40]. A study showed that IL-6
had no impact on the expression of CTSB mRNA and protein
levels in A-549 human lung epithelial cells [41]. However, other
Fig. 4 Schematic representation demonstrating the role of IL-6 in regulating expression and activity of CTSB, and in lymph node
metastasis in HRP-breast cancer cells. Exogenous IL-6 or IL-6 secreted from tumor-associated cells (e.g. adipocytes, fibroblasts and
monocytes/macrophages) binds to its receptor complex IL-6R/gp-130, which consequently increases expression and conversion of pro-
CTSB into active CTSB via its binding into lipid raft of cell membrane. The active form of CTSB secreted into extracellular space
enhances proteolytic activities cascades and degradation of ECM constituents. Cancer cells lose cell-to-cell contact, acquire invasive
phenotype and metastasize via lymphatic vessels into the regional lymph nodes.
668 S.A. Ibrahim et al.studies showed that IL-6 stimulated the expression of proteases
such as MMP-2 and MMP-9 and intracellular protease CTSB
and CTSL in C2C12 myotubes as a model of the muscle [42],
non-Hodgkin’s lymphomas [43], squamous cell carcinoma
[44] and in breast tumor-associated monocytes [27]. Although
many reports showed the potential role of IL-6 in regulating
CTSB expression, the present study is the first report addressed
this regulation in breast cancer. In this regard, results of this
study indicate that 25 ng/mL and 50 ng/mL IL-6 augmented
the expression and activity of CTSB in MCF-7 cells, suggesting
that CTSB may play a crucial role in IL-6-mediated enhanced
invasiveness phenotype of MCF-7 cells.
IL-6 and CTSB have been assigned as markers whose
expressions are associated with poor prognosis of breast cancer
patients [34,45]. A high level of IL-6 is associated with
increased tumor stage, lymph node infiltration, recurrence,
and treatment resistance in breast cancer patients [34,46,47].
In addition, local intratumoral IL-6 was found to regulate
breast cancer cell growth, metastasis, and self-renewal of can-
cer stem cells [48]. IL-6 is significantly upregulated in the
plasma of ER+ metastasized cancers, and essentially can be
utilized to distinguish between women with breast cancer
and healthy controls [30]. Nouh et al. [9] have previously
shown that CTSB is a potential prognostic marker and its
over-expression induces lymph-node metastasis in IBC
patients. In addition, inhibition of CTSB activity attenuates
ECM degradation and IBC cell invasion [8]. Patients suffering
from lung tissue damage (cystic fibrosis) show an increasedlevel of sputum IL-6 correlating with CTSB [49]. In this study,
Western blotting and ELISA data showed that IL-6 was over-
expressed in HRP-breast carcinoma tissues of pLNs as com-
pared to those of nLNs patients. In addition, an over-
expression of CTSB in HRP-breast carcinoma tissues of pLNs
when compared to nLNs patients was detected. Of particular
importance, the present findings indicate an existence of a pos-
itive correlation (r= 0.78, P< 0.01) between IL-6 and CTSB
in pLNs patients. Mechanistically, IL-6 induces CTSB activa-
tion via p38 MAPK and NFjb in human osteoblasts [25]. Of
note, NFjb regulates expression of CTSB via binding to the
promoter region of CTSB gene in Hela cells [50], suggesting
a mechanism may be exerted by IL-6 in stimulating CTSB
expression by HRP-breast carcinoma cells. Indeed, CTSB
secreted by carcinoma cells plays crucial role in the activation
of proteolytic pathways, degradation of ECM, motility and
invasion of carcinoma cells, which may ultimately lead to
lymph node metastasis (Fig. 4).
Conclusions
The present study demonstrated that IL-6 promotes invasive
properties of the low metastatic potential MCF-7 cells via
increasing expression and activity of CTSB. In addition, this
study validated the role of IL-6 in stimulating CTSB expres-
sion in human HRP-breast carcinoma tissues. Results showed
that IL-6 is upregulated and correlates with the expression of
CTSB levels in the carcinoma tissues of HRP-breast cancer
IL-6 and cathepsin B in hormonal-receptor positive breast cancer 669with pLNs when compared to nLN patients. Given the thera-
peutic modality of the monoclonal antibody against IL-6 in
clinical trials of different tumor entities [51,52], thus the pre-
sent results provided evidence that IL-6 as single agent or in
combination with CTSB are relevant therapeutic targets for
HRP-breast cancer with pLNs patients (Fig. 4). Further stud-
ies are warranted to fully identify signaling pathway(s) regulat-
ing IL-6/CTSB axis in different molecular subtypes of breast
cancer.
Study limitation
One limitation of this study is only MCF-7 cells tested; how-
ever, previous work performed by authors showed a modest
increased migratory phenotype of the triple negative breast
cancer cell line MDA-MB-231 upon incubation with IL-6
[53], suggesting a similar mechanism may be at least in part rel-
evant for other breast cancer cell lines. Nevertheless, it is doc-
umented that hormonal negative breast cell lines produced
autocrine IL-6, which prone the cells less or unresponsive to
exogenous IL-6 [54].
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